Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023

Eero Poukka, Hanna Nohynek, Sirkka Goebeler, Tuija Leino, Ulrike Baum
doi: https://doi.org/10.1101/2023.03.02.23286561

Article Information

doi 
https://doi.org/10.1101/2023.03.02.23286561
History 
  • May 5, 2023.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Eero Poukka1,2,*,
  2. Hanna Nohynek1,
  3. Sirkka Goebeler3,
  4. Tuija Leino1 and
  5. Ulrike Baum1
  1. 1Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland
  2. 2Department of Public Health, Faculty of Medicine, University of Helsinki, Yliopistonkatu 4, 00100 Helsinki, Finland
  3. 3Forensic Medicine Unit, Department of Government services, Finnish Institute for Health and Welfare, Mannerheimintie 166, 00300 Helsinki, Finland
  1. ↵*Corresponding author; email: eero.poukka{at}thl.fi
Back to top
Posted May 05, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Bivalent booster effectiveness against severe COVID-19 outcomes in Finland, September 2022 – March 2023
Eero Poukka, Hanna Nohynek, Sirkka Goebeler, Tuija Leino, Ulrike Baum
medRxiv 2023.03.02.23286561; doi: https://doi.org/10.1101/2023.03.02.23286561
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area